Recent developments for Picard Medical include regulatory compliance actions, financial results, and progress in artificial heart technology development.

• Picard Medical announced a 1-for-50 reverse stock split in July 2026 to comply with NYSE American listing standards; the share price declined significantly following the announcement [N2].
• The company reported a wider net loss in Q1 2026 despite revenue growth, reflecting ongoing financial challenges [N4].
• HC Wainwright & Co. initiated coverage of Picard Medical with a neutral recommendation in May 2026 [N5].
• Picard Medical reported successful in vivo implant studies for the Emperor Total Artificial Heart, indicating progress in product development [N3].
• The NYSE American accepted Picard Medical's Compliance Plan in July 2026, allowing the company to maintain its listing subject to quarterly reviews and milestones [S2].

Picard Medical has demonstrated progress in advancing its artificial heart technology, including successful in vivo implant studies for the Emperor Total Artificial Heart and plans to present data at key medical conferences. The acceptance of its Compliance Plan by the NYSE American allows the company to maintain its listing while working toward financial and operational milestones. These developments indicate ongoing execution in product development and regulatory engagement, which are critical in the medical device industry.

The company has reported sustained net losses over multiple years, with a significant net loss of $5.66 million in Q2 2026 and tight liquidity as indicated by a low cash ratio. Picard Medical received a notice of non-compliance from the NYSE American due to stockholders' equity and losses, necessitating a Compliance Plan and a reverse stock split that negatively impacted share price. The risk of delisting remains if compliance milestones are not met, which could reduce liquidity, market visibility, and access to financing. These financial and regulatory challenges pose risks to the company’s operational continuity and market presence.

Picard Medical operates in the specialized medical device sector focused on artificial heart technologies, a niche requiring significant technical expertise, regulatory approvals, and clinical validation. The company’s development of the Emperor Total Artificial Heart and its progress in in vivo implant studies suggest a technological moat based on proprietary design and clinical milestones. However, the company faces challenges related to financial sustainability and regulatory compliance, which may impact its ability to fully capitalize on its technological advances. The moat is primarily derived from its specialized product development and clinical progress in a complex and highly regulated medical field.

• NYSE American Listing Compliance Risk: Picard Medical received a notice of non-compliance with NYSE American listing standards due to stockholders' equity below required levels and net losses in recent years. The company’s continued listing depends on meeting milestones in an accepted Compliance Plan and passing quarterly reviews, with a deadline of November 8, 2027.
• Liquidity and Financial Sustainability Risk: The company reported limited cash reserves and a current ratio just above 1 as of June 30, 2026, alongside significant net losses, indicating tight liquidity and ongoing financial challenges that may affect its ability to fund operations and development.
• Market and Share Price Risk: The 1-for-50 reverse stock split implemented to maintain listing compliance led to a significant decline in share price, which may affect investor perception, market liquidity, and the company’s ability to raise capital.
• Regulatory and Development Risk: Picard Medical’s business depends on successful development, clinical validation, and regulatory approvals of its artificial heart technologies. Delays or failures in these areas could impact the company’s prospects and operational viability.

• Picard Medical, Inc. is a medical device company focused on developing artificial heart technologies, including the Emperor Total Artificial Heart.
• The company is incorporated in Delaware and headquartered in Tucson, Arizona.
• Picard Medical's common stock trades on the NYSE American under the ticker PMI.
• As of June 30, 2026, the company reported cash and cash equivalents of $38,000 and current assets of approximately $7.59 million, with current liabilities of about $7.45 million, resulting in a current ratio of 1.02 and a cash ratio of 0.01, indicating tight liquidity.
• The company reported a net loss of $5.66 million for the quarter ended June 30, 2026, and a basic EPS loss of $3.05 per share for the same period.
• Picard Medical has experienced net losses in three of its four most recent fiscal years, with stockholders' equity reported at approximately $3.8 million as of December 31, 2025.
• The company received a notice from the NYSE American in May 2026 for non-compliance with listing standards due to stockholders' equity and net losses, and subsequently submitted a Compliance Plan accepted by the exchange in July 2026, allowing continued listing subject to quarterly reviews and milestones.
• Picard Medical announced a 1-for-50 reverse stock split in July 2026 to maintain NYSE American listing compliance, which led to a significant share price decline.
• The company has reported progress in its artificial heart development, including successful in vivo implant studies for the Emperor Total Artificial Heart and plans to present data on the fully implantable version at medical conferences.
• Picard Medical's business updates and financial results have been covered extensively in recent news articles, including coverage of wider net losses despite revenue growth and analyst initiation of coverage with a neutral recommendation.
• The company is classified as a smaller reporting company and an emerging growth company, with no accelerated or large accelerated filer status.
• Picard Medical's executive compensation includes annual fees and stock option grants for non-management directors.
• The company faces risks related to its ability to regain compliance with NYSE American listing standards and the potential consequences of delisting, including reduced liquidity and financing challenges.